Patents by Inventor Frank Verdonck

Frank Verdonck has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10822425
    Abstract: The present invention relates to immunoglobulin single variable domain sequences that are directed against (as defined herein) OX40L, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such immunoglobulin single variable domain sequences. In particular these immunoglobulin single variable domain sequences can block binding of OX40L to OX40. The immunoglobulin single variable domains, compounds and constructs can be used for prophylactic, therapeutic or diagnostic purposes, such as for the treatment of inflammatory disease and/or disorder such as e.g. asthma, allergic asthma, chronic colitis, Crohn's disease, inflammatory bowel disease, and/or arthrosclerosis.
    Type: Grant
    Filed: October 27, 2017
    Date of Patent: November 3, 2020
    Assignee: Ablynx N.V.
    Inventors: Frank Verdonck, Sigrid Cornelis, Stephanie Staelens
  • Publication number: 20180362656
    Abstract: The present invention relates to immunoglobulin single variable domain sequences that are directed against (as defined herein) OX40L, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such immunoglobulin single variable domain sequences. In particular these immunoglobulin single variable domain sequences can block binding of OX40L to OX40. The immunoglobulin single variable domains, compounds and constructs can be used for prophylactic, therapeutic or diagnostic purposes, such as for the treatment of inflammatory disease and/or disorder such as e.g. asthma, allergic asthma, chronic colitis, Crohn's disease, inflammatory bowel disease, and/or arthrosclerosis.
    Type: Application
    Filed: October 27, 2017
    Publication date: December 20, 2018
    Applicant: Ablynx N.V
    Inventors: FRANK VERDONCK, Sigrid Cornells, Stephanie Staelens
  • Publication number: 20180171019
    Abstract: The present invention relates to immunoglobulin single variable domain sequences that are directed against (as defined herein) OX40L, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such immunoglobulin single variable domain sequences. In particular these immunoglobulin single variable domain sequences can block binding of OX40L to OX40. The immunoglobulin single variable domains, compounds and constructs can be used for prophylactic, therapeutic or diagnostic purposes, such as for the treatment of inflammatory disease and/or disorder such as e.g. asthma, allergic asthma, chronic colitis, Crohn's disease, inflammatory bowel disease, and/or arthrosclerosis.
    Type: Application
    Filed: October 27, 2017
    Publication date: June 21, 2018
    Applicant: Ablynx N.V
    Inventors: FRANK VERDONCK, Sigrid Cornells, Stephanie Staelens
  • Patent number: 9834611
    Abstract: The present invention relates to immunoglobulin single variable domain sequences that are directed against (as defined herein) OX40L, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such immunoglobulin single variable domain sequences. In particular these immunoglobulin single variable domain sequences can block binding of OX40L to OX40. The immunoglobulin single variable domains, compounds and constructs can be used for prophylactic, therapeutic or diagnostic purposes, such as for the treatment of inflammatory disease and/or disorder such as e.g. asthma, allergic asthma, chronic colitis, Crohn's disease, inflammatory bowel disease, and/or arthrosclerosis.
    Type: Grant
    Filed: December 31, 2014
    Date of Patent: December 5, 2017
    Assignee: Ablynx N.V.
    Inventors: Frank Verdonck, Sigrid Cornelis, Stephanie Staelens
  • Publication number: 20150218281
    Abstract: The present invention relates to immunoglobulin single variable domain sequences that are directed against (as defined herein) OX40L, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such immunoglobulin single variable domain sequences. In particular these immunoglobulin single variable domain sequences can block binding of OX40L to OX40. The immunoglobulin single variable domains, compounds and constructs can be used for prophylactic, therapeutic or diagnostic purposes, such as for the treatment of inflammatory disease and/or disorder such as e.g. asthma, allergic asthma, chronic colitis, Crohn's disease, inflammatory bowel disease, and/or arthrosclerosis.
    Type: Application
    Filed: December 31, 2014
    Publication date: August 6, 2015
    Applicant: ABLYNX N.V.
    Inventors: FRANK VERDONCK, SIGRID CORNELIS, STEPHANIE STAELENS
  • Patent number: 8962807
    Abstract: The present invention relates to immunoglobulin single variable domain sequences that are directed against (as defined herein) OX40L, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such immunoglobulin single variable domain sequences. In particular these immunoglobulin single variable domain sequences can block binding of OX40L to OX40. The immunoglobulin single variable domains, compounds and constructs can be used for prophylactic, therapeutic or diagnostic purposes, such as for the treatment of inflammatory disease and/or disorder such as e.g. asthma, allergic asthma, chronic colitis, Crohn's disease, inflammatory bowel disease, and/or arthrosclerosis.
    Type: Grant
    Filed: December 14, 2010
    Date of Patent: February 24, 2015
    Assignee: Ablynx N.V.
    Inventors: Frank Verdonck, Sigrid Cornelis, Stephanie Staelens
  • Publication number: 20130018175
    Abstract: The present invention relates to immunoglobulin single variable domain sequences that are directed against (as de-fined herein) OX40L, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such immunoglobulin single variable domain sequences. In particular these immunoglobulin single variable domain sequences can block binding of OX40L to OX40. The immunoglobulin single variable domains, compounds and constructs can be used for prophylactic, therapeutic or diagnostic purposes, such as for the treatment of inflammatory disease and/or disorder such as e.g. asthma, allergic asthma, chronic colitis, Crohn's disease, inflammatory bowel disease, and/or arthrosclerosis.
    Type: Application
    Filed: December 14, 2010
    Publication date: January 17, 2013
    Applicant: ABLYNX N.V.
    Inventors: Frank Verdonck, Sigrid Cornelis, Stephanie Staelens